Physician profile
Roberto Ramos
NPI 1962561852
$1,287.70
in general payments reported to CMS, 2019-2025
12 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $55.57 · 2021: $175 · 2022: $221 · 2023: $213 · 2024: $325 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673 · Entertainment: $32.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.98 |
| Entertainment | $32.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $446.07 | 2021-2025 | Total30, Precision 1, Precision7 |
| Bausch & Lomb Americas INC. | $229.14 | 2024-2025 | Miebo, Xiidra |
| Coopervision INC. | $163.65 | 2022-2024 | Misight Contact Lens, Ortho-K Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.68 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $123.35 | 2022-2024 | Acuvue |
| Allergan, INC. | $74.51 | 2020-2021 | |
| Optos, INC. | $32.18 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $18.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.06 | 2020 | |
| Shire North American Group INC | $17.55 | 2019 | |
| Alimera Sciences, INC. | $13.22 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.